OSX 001
Alternative Names: FAST-LNP gene therapy - OncoSenX; OSX-001; p53-targeted suicide gene therapy - OncoSenXLatest Information Update: 28 Jul 2024
At a glance
- Originator OncoSenX
- Class Antineoplastics; DNA; Gene therapies
- Mechanism of Action Apoptosis stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV)
- 22 Jun 2020 Preclinical trials in Solid tumours in USA (IV) before June 2020
- 22 Jun 2020 Pharmacodynamics data from preclinical studies in Solid tumours presented at 111th Annual Meeting of the American Association for Cancer Research - II (AACR-II-2020)